FDA Grants Priority Review to Genentech’s Cancer Immunotherapy … – Business Wire (press release)
Channel NewsAsia |
FDA Grants Priority Review to Genentech's Cancer Immunotherapy …
Business Wire (press release) SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application … Roche's Tecentriq combo wins fast FDA review in race to catch rivals |
